Navigation Links
Larynx preservation preferred over total laryngectomy
Date:2/1/2008

Patients with locally advanced laryngopharyngeal cancers who receive radical chemoradiation have significantly better voice outcomes during the 12 months following treatment when compared with patients who have undergone a total laryngectomy and surgical voice restoration, according to a study in the February 1 issue of the International Journal for Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

The conventional treatment for patients with advanced squamous carcinoma of the larynx has traditionally been a total laryngectomy, which is the removal of the voice box, with or without radiation; however, this treatment has several serious side effects, including natural-voice loss, altered food-swallowing function and a permanent opening in the trachea.

Researchers in this study, conducted jointly by the Royal Marsden Hospital Head and Neck Unit and The Institute of Cancer Research, both in London, sought to determine if larynx preservation through chemoradiation would result in improved voice results and serve as a suitable alternative to total laryngectomy, which, in turn, would remove the need for surgery and all of the related potential side effects and risks.

Twenty-one patients, both male and female, with a median age of 65 years old, who were diagnosed with Stage III or IV laryngopharyngeal cancer, were given induction chemotherapy followed by radical chemoradiation. The researchers then used electroglottography placing electrodes alongside the larynx to electronically record and analyze the voice function of the patients before treatment and at one, six and 12 months after treatment. This is the first study of its kind to use electroglottography as an assessment technique.

Patients were asked to read a standard passage and pronounce vowel sounds into a microphone that sat at the same distance from the mouth of each patient. The researchers then used these recordings to measure jitter in the voice, maximum phonation time and words per minute.

Single voice recordings were also taken from 21 patients, with a median age of 65 years old, who received a total laryngectomy and surgical voice restoration, as well as from 21 normal controls of the same median age group.

The researchers found that preservation of the larynx through chemoradiation did not always return voice quality to exactly how it was before the tumor was present, but it did provide for significantly better voice outcomes when compared to removing the larynx through surgery. At 12 months after treatment, the patients receiving chemoradiation had normal maximum phonation time and words per minute, but less than normal jitter.

This study is important because it offers patients reassurance that if they undergo organ preservation, it is statistically proven that their voice will be better than if they undergo surgery. We can reassure patients that their voice is likely to recover from the immediate effects of chemoradiation, said Kevin Harrington, M.B.B.S., clinical senior lecturer at The Institute of Cancer Research. This study should also allay the concerns of surgeons that laryngopharyngeal cancer patients cannot be successfully treated with chemoradiation with good functional outcome.


'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Therapeutic Radiology and Oncology
Source:Eurekalert

Related medicine news :

1. New research suggests hearts are experts at self-preservation
2. The aye-ayes have it: The preservation of color vision in a creature of the night
3. Mylan Declares Quarterly Preferred Stock Dividend
4. NHP Increases Its Quarterly Common Dividend by $0.03 and Declares Its Quarterly Cash Dividends on Common Stock and Series B Preferred Stock
5. Wyeth Declares Common and Preferred Stock Dividends
6. Smart Balance Announces Conversion of Convertible Preferred Stock
7. HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. Nationwide Respiratory Signs Preferred Pulse Oximetry Agreement with Masimo
10. BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends
11. Karmanos Cancer Center Most Preferred Hospital for Cancer Care According to 2007 Survey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... , ... Mediaplanet is proud to announce the launch of ... treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage ... in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This ...
(Date:12/2/2016)... ... , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology ... health technology on the market can deliver all that rejiva can. , “Rejiva promotes ... their health than the usual heart rate and steps taken”, adds Evens Augustin, CEO ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today ... intelligent, connected applications, was named the best Sales Team of 2016 as part ... was made today by the Software & Information Industry Association (SIIA), the principal ...
(Date:11/30/2016)... ... , ... "I hate when the mixture of saliva and toothpaste runs down ... from Bridgewater, N.J. "I thought that there had to be a way to prevent ... patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush handle onto ...
(Date:11/30/2016)... U.K. (PRWEB) , ... November 30, 2016 , ... ... address the tech functions and stylish design wanted by today’s consumers at an ... Cronovo Co-Founder Darin Philip says the new watch is “a game changer” when ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... WOONSOCKET, R.I. , Dec. 2, 2016 ... hold its annual Analyst Day in New York City on Thursday, December ... the CVS Health leadership team will provide an in-depth ... and enhance shareholder value. The company will also discuss ... audio and video webcast of the event will be ...
(Date:12/2/2016)... 2, 2016 Orthopedic Implants (Including Spinal ... Expected to Gain a Significant Market Share Owing to a ... ... According to a new report by ... Sterile Packaging: Clamshell Product Type Segment Projected to Witness a ...
(Date:12/2/2016)... N.J. , Dec. 2, 2016   CytoSorbents ... immunotherapy leader commercializing its European Union approved CytoSorb ... and cardiac surgery patients worldwide, announced that Dr. ... the 9th Annual LD Micro Main Event ... , 2016 at the Luxe Sunset Boulevard Hotel in ...
Breaking Medicine Technology: